Stockreport

Sienna Biopharmaceuticals Announces SNA-120 (0.05%) Biopsy Data Demonstrate Positive Impact on Key Inflammatory Cytokines, including IL-23 and IL-17, in Psoriasis

SIENNA BIOPHARMACEUTICALS  (SNNA) 
Last sienna biopharmaceuticals earnings: 8/8 04:18 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.siennabio.com/node/5806
PDF -- Biopsy data support strong clinical effect observed in Phase 2 trials with SNA-120  -- Following Positive End-of-Phase 2 meeting with FDA, Sienna continues toward en [Read more]